Natixis
PRME icon

Natixis’s Prime Medicine PRME Stock Holding History

Natixis’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$166 Buy
+45
New +$149 ﹤0.01% 1132

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Natixis's PRME Position: Q2 2026 in Review

Natixis opened a new position in Prime Medicine (PRME) in Q2 2026: 45 shares worth $166. The stake represents ﹤0.01% of the portfolio and ranks #1132 among its holdings.

187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Natixis held 45 shares of Prime Medicine worth $166 as of Q2 2026.
  • Prime Medicine was a new Natixis position in Q2 2026.
  • Prime Medicine made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #1132 holding.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.